Clinical Trials Logo

ABPA clinical trials

View clinical trials related to ABPA.

Filter by:
  • None
  • Page 1

NCT ID: NCT05903612 Withdrawn - Asthma Clinical Trials

Allergic Bronchopulmonary Aspergillosis Prescreening Study

Start date: January 10, 2024
Phase:
Study type: Observational

This prescreening study is being conducted to diagnose ABPA in selected patients with asthma and to increase the potential number of eligible participants for the ongoing Study 601-0018 of PUR1900 in subjects with ABPA. See: NCT05667662. Additionally, this prescreening study may provide information that could assist the conduct of future studies conducted by Pulmatrix.

NCT ID: NCT05667662 Terminated - ABPA Clinical Trials

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The main questions it aims to answer are: 1. Is PUR1900 safe and well tolerated in adults with asthma and ABPA? 2. Is there an effect of daily administration of PUR1900 on potential outcome measures in adults with asthma and ABPA? 3. Is there fungal resistance to A. fumigatus? This study includes a 28-day screening period, a 112-day (16-week) treatment period, and a 56-day (8 week) observation period. Participants will take either 40mg of PUR1900, 20 mg of PUR1900 or Placebo for 112 days and complete an eDairy, answer questions about their asthma and complete peak respiratory flow measurements at home. They will come to the clinic approximate once a month during the treatment period and complete study assessments. At the end of the observation period participants will complete one more clinic visit. Participants who complete this study may be given the opportunity to continue on study drug in an open label extension study.

NCT ID: NCT04108962 Withdrawn - Severe Asthma Clinical Trials

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Start date: December 23, 2019
Phase: Phase 4
Study type: Interventional

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

NCT ID: NCT03643185 Recruiting - ABPA Clinical Trials

Cytokine Profile of Allergic Bronchopulmonary Aspergillosis

Start date: December 2014
Phase:
Study type: Observational

The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic bronchopulmonary aspergillosis).

NCT ID: NCT02853175 Completed - Clinical trials for Pulmonary Cystic Fibrosis

Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis

MRAB
Start date: January 2014
Phase:
Study type: Observational

In this diagnostic study, the aim is at evaluating the diagnostic accuracy of MRI (Magnetic Resonance Imaging) to detect allergic broncho-pulmonary aspergillosis in patients with cystic fibrosis.